Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.

Bernstein V, Ellard SL, Dent SF, Tu D, Mates M, Dhesy-Thind SK, Panasci L, Gelmon KA, Salim M, Song X, Clemons M, Ksienski D, Verma S, Simmons C, Lui H, Chi K, Feilotter H, Hagerman LJ, Seymour L.

Breast Cancer Res Treat. 2018 Jan;167(2):485-493. doi: 10.1007/s10549-017-4538-4. Epub 2017 Oct 13.

PMID:
29027598
2.

Precision spherical nucleic acids for delivery of anticancer drugs.

Bousmail D, Amrein L, Fakhoury JJ, Fakih HH, Hsu JCC, Panasci L, Sleiman HF.

Chem Sci. 2017 Sep 1;8(9):6218-6229. doi: 10.1039/c7sc01619k. Epub 2017 Jul 5.

3.

Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer.

Ferrario C, Strepponi I, Esfahani K, Charamis H, Langleben A, Scarpi E, Nanni O, Miller WH Jr, Panasci LC.

PLoS One. 2016 Dec 19;11(12):e0167906. doi: 10.1371/journal.pone.0167906. eCollection 2016.

4.

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.

Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ.

Lancet. 2016 Dec 17;388(10063):2997-3005. doi: 10.1016/S0140-6736(16)32389-3. Epub 2016 Nov 29.

PMID:
27908454
5.

Complete response and long-term survival of leptomeningeal carcinomatosis from breast cancer with maintenance endocrine therapy.

Almajed MM, Esfahani K, Pelmus M, Panasci L.

BMJ Case Rep. 2016 Jun 2;2016. pii: bcr2016215525. doi: 10.1136/bcr-2016-215525.

6.

Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer.

McLean J, Rho YS, Kuruba G, Mamo A, Gilabert M, Kavan T, Panasci L, Melnychuk D, Batist G, Kavan P.

Clin Colorectal Cancer. 2016 Jun;15(2):135-40. doi: 10.1016/j.clcc.2015.10.003. Epub 2015 Oct 21.

PMID:
26553578
7.

Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.

Shen D, Guo CC, Wang J, Qiu ZK, Sai K, Yang QY, Chen YS, Chen FR, Wang J, Panasci L, Chen ZP.

Oncol Rep. 2015 Nov;34(5):2715-21. doi: 10.3892/or.2015.4232. Epub 2015 Aug 27.

PMID:
26329778
8.

Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan.

Abu-Sanad A, Wang Y, Hasheminasab F, Panasci J, Noë A, Rosca L, Davidson D, Amrein L, Sharif-Askari B, Aloyz R, Panasci L.

Front Pharmacol. 2015 Jul 22;6:147. doi: 10.3389/fphar.2015.00147. eCollection 2015.

9.
10.

Hormonal manipulation with letrozole in the treatment of metastatic malignant pecoma.

Le P, Garg A, Brandao G, Abu-Sanad A, Panasci L.

Curr Oncol. 2014 Jun;21(3):e518-20. doi: 10.3747/co.21.1849.

11.

Aromatase inhibition in relapsing low malignant potential serous tumours of the ovary.

Esfahani K, Ferrario C, Le P, Panasci L.

BMJ Case Rep. 2014 Jun 12;2014. pii: bcr2014204287. doi: 10.1136/bcr-2014-204287.

12.

Effects of dna-dependent protein kinase inhibition by NU7026 on dna repair and cell survival in irradiated gastric cancer cell line N87.

Niazi MT, Mok G, Heravi M, Lee L, Vuong T, Aloyz R, Panasci L, Muanza T.

Curr Oncol. 2014 Apr;21(2):91-6. doi: 10.3747/co.21.1509.

13.

Pharmacological targeting of eIF4E in primary CLL lymphocytes.

Martinez-Marignac V, Shawi M, Pinedo-Carpio E, Wang X, Panasci L, Miller W, Pettersson F, Aloyz R.

Blood Cancer J. 2013 Sep 13;3:e146. doi: 10.1038/bcj.2013.43. No abstract available.

14.

Systemic cancer therapy: achievements and challenges that lie ahead.

Palumbo MO, Kavan P, Miller WH Jr, Panasci L, Assouline S, Johnson N, Cohen V, Patenaude F, Pollak M, Jagoe RT, Batist G.

Front Pharmacol. 2013 May 7;4:57. doi: 10.3389/fphar.2013.00057. eCollection 2013.

15.

A real-life experience using panitumumab in chemo-refractory metastatic colorectal cancer patients: a retrospective analysis at the Jewish General Hospital, 2009-2012.

Mamo A, Nogueira MC, Batist G, Palumbo M, Panasci L, Ferrario C, Chaudhury P, Metrakos P, Kavan P.

Curr Oncol. 2013 Apr;20(2):e107-12. doi: 10.3747/co.20.1271.

16.

Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond.

Davidson D, Amrein L, Panasci L, Aloyz R.

Front Pharmacol. 2013 Jan 31;4:5. doi: 10.3389/fphar.2013.00005. eCollection 2013.

17.

Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?

Lovato A, Panasci L, Witcher M.

Front Pharmacol. 2012 Dec 27;3:202. doi: 10.3389/fphar.2012.00202. eCollection 2012.

18.

The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro.

Amrein L, Shawi M, Grenier J, Aloyz R, Panasci L.

Int J Cancer. 2013 Jul;133(1):247-52. doi: 10.1002/ijc.27989. Epub 2013 Jan 15.

19.

The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.

Davidson D, Wang Y, Aloyz R, Panasci L.

Invest New Drugs. 2013 Apr;31(2):461-8. doi: 10.1007/s10637-012-9886-7. Epub 2012 Oct 9.

20.

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.

Sahebjam S, Aloyz R, Pilavdzic D, Brisson ML, Ferrario C, Bouganim N, Cohen V, Miller WH Jr, Panasci LC.

Br J Cancer. 2011 Oct 25;105(9):1342-5. doi: 10.1038/bjc.2011.402. Epub 2011 Oct 4.

21.

ZRF4, a combi-molecule with increased efficacy as compared with the individual components in chronic lymphocytic leukemia lymphocytes in vitro.

Amrein L, Rachid Z, Jean-Claude B, Soulières D, Aloyz R, Panasci L.

Leukemia. 2011 Sep;25(9):1512-6. doi: 10.1038/leu.2011.110. Epub 2011 Jun 7. No abstract available.

22.

Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells.

Davidson D, Grenier J, Martinez-Marignac V, Amrein L, Shawi M, Tokars M, Aloyz R, Panasci L.

Invest New Drugs. 2012 Aug;30(4):1736-42. doi: 10.1007/s10637-011-9678-5. Epub 2011 May 13.

PMID:
21567185
23.

Trastuzumab and vinorelbine in early stages of HER2-positive breast cancer.

Ferrario C, Wong A, Gao T, Bouganim N, Aloyz R, Panasci LC.

J Chemother. 2011 Feb;23(1):32-5.

PMID:
21482492
24.

Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy.

Amrein L, Davidson D, Shawi M, Petruccelli LA, Miller WH Jr, Aloyz R, Panasci L.

Leuk Res. 2011 Aug;35(8):1080-6. doi: 10.1016/j.leukres.2011.01.004. Epub 2011 Feb 1.

PMID:
21281966
25.

Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells.

Davidson D, Coulombe Y, Martinez-Marignac VL, Amrein L, Grenier J, Hodkinson K, Masson JY, Aloyz R, Panasci L.

Invest New Drugs. 2012 Jun;30(3):1248-56. doi: 10.1007/s10637-010-9626-9. Epub 2011 Jan 11.

PMID:
21221710
26.

A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.

Hebb J, Assouline S, Rousseau C, Desjardins P, Caplan S, Egorin MJ, Amrein L, Aloyz R, Panasci L.

Cancer Chemother Pharmacol. 2011 Sep;68(3):643-51. doi: 10.1007/s00280-010-1530-7. Epub 2010 Dec 1.

PMID:
21120481
27.

Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).

Pritchard KI, Rolski J, Papai Z, Mauriac L, Cardoso F, Chang J, Panasci L, Ianuli C, Kahan Z, Fukase K, Lindemann JP, Macpherson MP, Neven P.

Breast Cancer Res Treat. 2010 Sep;123(2):453-61. doi: 10.1007/s10549-010-1022-9. Epub 2010 Jul 15.

PMID:
20632084
28.

Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study.

Puts MT, Monette J, Girre V, Pepe C, Monette M, Assouline S, Panasci L, Basik M, Miller WH Jr, Batist G, Wolfson C, Bergman H.

Crit Rev Oncol Hematol. 2011 May;78(2):138-49. doi: 10.1016/j.critrevonc.2010.04.003. Epub 2010 May 4.

PMID:
20444620
29.

Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase.

Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M.

Endocr Relat Cancer. 2010 Jun 1;17(2):351-60. doi: 10.1677/ERC-09-0252. Print 2010 Jun.

30.

Different impact of excision repair cross-complementing group 1 on survival.

Panasci LC.

J Clin Oncol. 2010 Apr 1;28(10):e163; author reply e164. doi: 10.1200/JCO.2009.26.6619. Epub 2010 Feb 16. No abstract available.

PMID:
20159805
31.

Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.

Trudeau ME, Clemons MJ, Provencher L, Panasci L, Yelle L, Rayson D, Latreille J, Vandenberg T, Goel R, Zibdawi L, Rahim Y, Pouliot JF.

J Clin Oncol. 2009 Dec 10;27(35):5906-10. doi: 10.1200/JCO.2009.22.7504. Epub 2009 Oct 26.

PMID:
19858391
32.

Primary del 17 chronic lymphocytic leukaemia lymphocytes are hypersensitive to dasatinib in vitro.

Amrein L, Panasci L, Gibson SB, Johnston JB, Soulières D, Aloyz R.

Br J Haematol. 2009 Nov;147(3):396-8. doi: 10.1111/j.1365-2141.2009.07814.x. Epub 2009 Sep 2. No abstract available.

33.

Re: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

Panasci LC.

J Clin Oncol. 2009 Sep 10;27(26):e111; author reply e112-3. doi: 10.1200/JCO.2009.23.8022. Epub 2009 Aug 10. No abstract available.

PMID:
19667259
34.

Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer.

Ferrario C, Davidson A, Bouganim N, Aloyz R, Panasci LC.

Ann Oncol. 2009 Apr;20(4):792-5. doi: 10.1093/annonc/mdp019. Epub 2009 Feb 17. No abstract available.

PMID:
19223574
35.

Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro.

Amrein L, Hernandez TA, Ferrario C, Johnston J, Gibson SB, Panasci L, Aloyz R.

Br J Haematol. 2008 Dec;143(5):698-706. doi: 10.1111/j.1365-2141.2008.07418.x .

PMID:
19062342
36.

Docetaxel plus cyclophosphamide in adjuvant breast cancer.

Ferrario C, Panasci LC.

J Clin Oncol. 2007 Sep 20;25(27):4327; author reply 4327. No abstract available.

PMID:
17878491
37.

ERCC1 and non-small-cell lung cancer.

Panasci L, Cohen V.

N Engl J Med. 2007 Jun 14;356(24):2540; author reply 2540-1. No abstract available.

PMID:
17575589
39.

Clinical response of O(6)-methylguanine-DNA methyltransferase levels to 1,3-(2-chloroethyl)-1-nitrosourea chemotherapy in glioma patients.

Chen ZP, Yarosh D, Garcia Y, Tampieri D, Mohr G, Langleben A, Panasci LC.

Neurosurg Focus. 1998 Jun 15;4(6):e3.

PMID:
17154443
40.

Xenografts of human hepatocellular carcinoma: a useful model for testing drugs.

Huynh H, Soo KC, Chow PK, Panasci L, Tran E.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4306-14.

41.

Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer.

Panasci LC.

J Clin Oncol. 2006 May 20;24(15):2392; author reply 2392. No abstract available.

PMID:
16710042
42.

Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.

Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR, Panasci L.

J Clin Oncol. 2006 Jun 20;24(18):2773-8. Epub 2006 May 8.

PMID:
16682726
43.

Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia.

Césaire R, Olière S, Sharif-Askari E, Loignon M, Lézin A, Olindo S, Panelatti G, Kazanji M, Aloyz R, Panasci L, Bell JC, Hiscott J.

Oncogene. 2006 Jan 19;25(3):349-58.

PMID:
16186807
45.

Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis.

Xu ZY, Loignon M, Han FY, Panasci L, Aloyz R.

J Pharmacol Exp Ther. 2005 Aug;314(2):495-505. Epub 2005 Apr 20.

46.

A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer.

Mackenzie MJ, Hirte HW, Glenwood G, Jean M, Goel R, Major PP, Miller WH Jr, Panasci L, Lorimer IA, Batist G, Matthews S, Douglas L, Seymour L.

Invest New Drugs. 2005 Mar;23(2):165-70.

PMID:
15744593
48.

Polyethyleneimine grafted with pluronic P85 enhances Ku86 antisense delivery and the ionizing radiation treatment efficacy in vivo.

Belenkov AI, Alakhov VY, Kabanov AV, Vinogradov SV, Panasci LC, Monia BP, Chow TY.

Gene Ther. 2004 Nov;11(22):1665-72.

PMID:
15470482
49.

Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer.

Labrie F, Champagne P, Labrie C, Roy J, Laverdière J, Provencher L, Potvin M, Drolet Y, Pollak M, Panasci L, L'Espérance B, Dufresne J, Latreille J, Robert J, Samson B, Jolivet J, Yelle L, Cusan L, Diamond P, Candas B.

J Clin Oncol. 2004 Mar 1;22(5):864-71.

PMID:
14990642
50.

Imatinib sensitizes CLL lymphocytes to chlorambucil.

Aloyz R, Grzywacz K, Xu ZY, Loignon M, Alaoui-Jamali MA, Panasci L.

Leukemia. 2004 Mar;18(3):409-14.

PMID:
14712290

Supplemental Content

Loading ...
Support Center